The Neuroscience of Being Human

The Neuroscience of Prescription Stimulants

How methylphenidate and amphetamine salts treat ADHD by raising tonic dopamine in a brain that is dopamine-deficient at baseline, why the same drugs in a non-deficient brain produce a fundamentally different effect, what cognitive enhancement myths get wrong, and what the evidence reveals about diversion, misuse and the long-term trajectory of legitimate use

1,610-word article with 8 Harvard references.

The targets: dopamine and noradrenaline transporters

Methylphenidate and amphetamine both elevate synaptic dopamine and noradrenaline, but they do so by different mechanisms. Methylphenidate is a competitive blocker of the dopamine transporter and the noradrenaline transporter. It binds to the transporter, prevents reuptake of the neurotransmitter from the synapse back into the presynaptic neuron, and the resulting accumulation increases signalling at postsynaptic receptors. The drug requires the neurons to be firing to produce its effect: no firing, no release, no accumulation.

Amphetamine is more aggressive. It enters the presynaptic neuron through the same transporters, displaces dopamine and noradrenaline from their storage vesicles into the cytoplasm, and reverses the direction of the transporters so that the neurotransmitters are pumped out into the synapse rather than back in. The result is release that is partially independent of neuronal firing. The transporter, instead of clearing the synapse, becomes the conduit for filling it. This is why amphetamine produces stronger and more sustained dopamine elevation than methylphenidate at equivalent therapeutic-equivalent doses, and why its abuse profile is also stronger (Faraone, 2018).

ADHD: dopamine deficiency and the paradox of stimulant calming

Volkow et al. (2009), using PET imaging with a dopamine D2/D3 receptor radioligand, demonstrated that adults with ADHD show reduced dopamine transporter and receptor availability in the ventral striatum compared with neurotypical controls. The finding supports a model in which ADHD involves a tonic dopamine deficit: the baseline dopamine signal in reward and motivation circuits is below the level required for sustained engagement with non-novel, non-immediately-rewarding tasks. The brain is not understimulated in the moment-to-moment sense of needing more excitement. It is undermotivated at the level of the neurochemistry that converts intention into sustained behaviour.

Therapeutic doses of stimulants raise tonic dopamine signalling towards the level seen in neurotypical controls. The clinical effect is the opposite of what an outside observer might predict. Hyperactive children become calmer. Distractible adults become more focused. The drug does not sedate. It supplies the neurochemistry that the brain was deficient in, and the regulatory systems that depend on adequate dopamine signalling, including the prefrontal cortex's capacity to inhibit prepotent responses, begin to function more effectively. The behavioural change is not pharmacological suppression. It is restored regulation.

The neurotypical brain meets the same drug: a different story

The same therapeutic dose of methylphenidate or amphetamine, given to a brain that does not have an underlying dopamine deficit, produces a different result. Volkow et al. (2002) measured dopamine release in healthy adults given oral methylphenidate and documented elevations in striatal dopamine signalling that were associated with self-reported euphoria, increased energy, and a sense of cognitive sharpness. The brain that already had adequate baseline dopamine was pushed into supranormal signalling, producing the experience that drives recreational and study-aid use.

Supranormal mesolimbic dopamine signalling is the neurobiological signature of addictive reward. The same circuits that respond to cocaine and amphetamine in their illicit forms are activated by methylphenidate and dexamphetamine in their prescription forms. The difference is dose, route, and pattern of use. Oral, slowly absorbed, therapeutically dosed prescription stimulants produce gradual elevations that carry meaningful but limited addictive liability for most users. Crushed and insufflated, or taken at supratherapeutic oral doses, the same drugs produce rapid, high-amplitude dopamine surges that are pharmacologically indistinguishable from the corresponding illicit stimulants.

The cognitive enhancement question: what the rigorous evidence shows

Ilieva et al. (2015) conducted a meta-analysis of placebo-controlled studies examining the cognitive effects of acute amphetamine and methylphenidate administration in healthy, non-ADHD adults. The findings were sobering for those who view prescription stimulants as a cognitive performance enhancer. Effects on simple reaction time and basic working memory tasks were small but detectable. Effects on more complex cognitive performance, including reasoning, planning, and learning of novel material, were inconsistent and frequently absent. Subjective reports of improved focus and productivity exceeded the objective performance gains by a substantial margin. Users felt they were performing better. They were not necessarily performing better.

The dissociation between subjective and objective effect is itself a clue to the underlying neurochemistry. Stimulants increase the salience of whatever the user is doing, the dopaminergic signal that tags an activity as worth attending to. The student who takes amphetamine to study finds the act of studying more rewarding and engages with it for longer. Whether they actually learn more is a separate question, and the answer appears to be: not reliably, and not by much. The drug supplies motivation and salience. It does not supply intellectual capacity that was not already there.

Long-term trajectory: legitimate treatment and the substance use question

A persistent concern about prescription stimulant treatment for ADHD has been whether long-term exposure to a controlled drug during childhood and adolescence might increase the risk of subsequent substance use disorder. Quinn et al. (2017), analysing a large national cohort using a within-individual design that controlled for time-stable confounders, found the opposite. Periods of stimulant medication were associated with reduced rates of substance-related events compared with periods off medication in the same individuals. The protective effect was most pronounced for stimulant-related substance use, suggesting that adequately treated ADHD reduces the self-medication trajectory that drives much non-prescribed stimulant use.

The finding does not eliminate the need for careful prescribing, monitoring, and management of diversion risk. It does locate the risk profile correctly. The danger is not in the brain that has ADHD and is treated for it. The danger is in the brain that does not have ADHD and acquires the medication anyway, or in the brain that has ADHD and uses the medication outside the dosing pattern that produces the therapeutic rather than the recreational effect.